aibio
Company Updates ·
StimCell hires Stonegate Capital Markets as non-exclusive advisor
The advisor will introduce investors and strategic partners for transactions the company approves, under an agreement effective August 24, 2026.
STME Stimcell Energetics Inc.
Stimcell Energetics (STME) news
Latest Stimcell Energetics news
We have not published a story on Stimcell Energetics yet. When there is news, it will appear here.
What Stimcell Energetics does
Stimcell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications, including aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. Its primary focus is its eBalance Technology, a microcurrent technology the company acquired in 2014 and says may be used to manage complications of diseases such as diabetes, insulin resistance, neuropathy, poor kidney function, high blood pressure and metabolic syndrome. The technology is the basis of two medical device systems: the eBalance Pro System, designed for healthcare professionals in a clinical setting, and the eBalance Home System, designed for patients to use at home. Both are intended for temporary relief of pain associated with sore muscles. Due to the company's financial situation, research was suspended in the year ended May 31, 2023, and its Health Canada certification licences were suspended on June 5, 2023. In February 2025 the company engaged ADM Tronics Unlimited, Inc. to redesign the eBalance Home device into a smaller, more affordable consumer unit. The text says new clinical trials are suspended and are not being reviewed.
| Product or program | What it is | Stage |
|---|---|---|
| eBalance Pro System | Microcurrent medical device system for use by healthcare professionals in a clinical setting | Health Canada certification suspended June 5, 2023 |
| eBalance Home System | Microcurrent device designed for patients to use at home for symptoms | Being redesigned with ADM Tronics Unlimited, Inc. |
| eBalance Technology | Microcurrent technology for diabetes and related ailments | Research suspended |
Stimcell Energetics annual financials
Questions about Stimcell Energetics
What is the ticker symbol of Stimcell Energetics?
Stimcell Energetics Inc. trades under the ticker STME on OTC.
Where is Stimcell Energetics listed?
Stimcell Energetics Inc. is listed on OTC.
Which country or territory is Stimcell Energetics listed under?
Our directory records Stimcell Energetics Inc. under United States.
Does aibio.space cover Stimcell Energetics?
aibio.space lists Stimcell Energetics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What does Stimcell Energetics develop?
Stimcell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications, including aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. Its primary focus is its eBalance Technology, a microcurrent technology the company acquired in 2014 and says may be used to manage complications of diseases such as diabetes, insulin resistance, neuropathy, poor kidney function, high blood pressure and metabolic syndrome.
What is eBalance Pro System from Stimcell Energetics?
eBalance Pro System: Microcurrent medical device system for use by healthcare professionals in a clinical setting Stage: Health Canada certification suspended June 5, 2023.
What is eBalance Home System from Stimcell Energetics?
eBalance Home System: Microcurrent device designed for patients to use at home for symptoms Stage: Being redesigned with ADM Tronics Unlimited, Inc..
How much cash does Stimcell Energetics have?
$6,883 in cash at Aug 31, 2026, per its 10-Q.
What is the latest Stimcell Energetics (STME) stock news?
Our latest story on Stimcell Energetics, dated Sep 8, 2026: "StimCell hires Stonegate Capital Markets as non-exclusive advisor". The advisor will introduce investors and strategic partners for transactions the company approves, under an agreement effective August 24, 2026. Source.
How can I follow Stimcell Energetics (STME) news?
Press Follow on this page to add Stimcell Energetics to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Stimcell Energetics so far, in Company Updates.
Investor discussion: Stimcell Energetics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
Listing details
- Company
- Stimcell Energetics Inc.
- Ticker
- STME
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction